Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Actinium Pharmaceuticals, Inc. (ATNM) is a Biotechnology company based in US with a market capitalization of $28.2M. Free cash flow was negative at -$24.7M. This page tracks ATNM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 31 employees · IPO Dec 27, 2012

Valuation

Valuation & price

$1.25as of May 17, 2026· -30.2% vs 52w high

P/E ratio

Latest-FY diluted EPS

3.60

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$1.79$1.34$0.90Jul 25Jan 26Jul 26
$0.9052-week range$1.79
Loading valuation history…

Fundamentals

Key fundamentals

$28.2M

Market cap

Revenue growth (YoY)

100.0%

Gross margin

-$24.7M

Free cash flow (USD)

-$46.3M

Net debt

Net cash position

3.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$0$90K

Free cash flow by year

20162025

-$20.8M-$24.7M

Gross margin by year

20212025

54.2%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 18, 2026Filing

    Compliance Plan Submitted

  • 8-K eventMay 29, 2026Filing

    Delisting Notice

  • Quarterly reportMay 8, 2026Filing

    10-Q Filed

Questions

Frequently asked questions

What is Actinium Pharmaceuticals, Inc.'s market cap?

Actinium Pharmaceuticals, Inc. (ATNM) has a market capitalization of $28.2M.

What is ATNM's P/E ratio?

A meaningful P/E ratio is not available for ATNM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ATNM's price-to-book (P/B) ratio?

ATNM trades at 3.60 times book value per share.

Are insiders buying ATNM stock?

SEC Form 4 filings show no open-market insider buys at Actinium Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.